Parameter
| Biomarker | ctDNA | Full name | Circulating tumor DNA | Molecular Type | Nucleic acid (DNA from tumor tissue) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognostic assessment, minimal residual disease monitoring, and clonal evolution analysis |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Blood and lymphoid tissue | Test Sample / Technology Platform | Plasma (LyV4.0 ctDNA CAPP-seq, whole-genome low coverage sequencing, targeted NGS) | ||
| Pathobiological Mechanisms | DNA fragments released by tumor cells reflect tumor burden and genetic mutation status, with high levels prior to treatment indicating poor prognosis and being highly correlated with PET/CT findings. | ||||
| Clinical Availability Status | Research validation/clinical translation phase: The 3-year PFS prediction C-index was 64.9%, which improved to 69.8% when combined with IPS, enabling the identification of high-risk patients. | ||||
| Notes and Dynamics | The most frequently mutated gene is STAT6, with significant differences in mutation profiles across subtypes; it enables dynamic tracking of disease progression and complements imaging assessments. | ||||